Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Why Pfizer Stock Is Lower After a Beat-and-Raise Quarter

Pfizer stock is down Tuesday even after the drugmaker reported higher-than-expected Q3 earnings and raised its full-year outlook.

Kiplinger

Cheap Mexican Drugs Forcing Canadian Cartels to Export Meth to Other Countries

Canadian manufacturers of methamphetamine are being pushed to begin selling their product in foreign markets after being unable to compete with cheaper product from Mexico circulating in their home market.

Latin Times

Monte Rosa Almost Doubles — Up 94% — On A Massive Deal With Novartis

Monte Rosa Therapeutics shares nearly doubled Monday on a deal with Novartis to develop treatments for immune system conditions.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

More than half of WA pharmacies choosing not to stock vapes, survey shows

Exclusive: Uncertainty over regulations and discomfort over stocking a product not evaluated by drugs regulator among reasons given

The Guardian - AU

AstraZeneca ‘said it could cut UK jobs’ if biodiversity drug levy is introduced

Biotech giant’s alleged comments come as world leaders at Cop16 discuss how to share benefits from genetic code discoveries fairly

The Guardian - UK

Missouri Seeks to Block Access to Abortion Pill Because It's Stopping Teens from Getting Pregnant

Fewer teenage pregnancies means a population loss for the states, as well as "diminishment of political representation and loss of federal funds."

Latin Times

3 Pharma Stocks to Watch as Gene Therapy Gains Momentum

The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and improve treatment options. Given this favorable trend, it could be wise to watch strong pharma stocks such as Vertex Pharmaceuticals (VRTX), Wave Life Sciences (WVE), and Poseida Therapeutics (PSTX). Read more.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

US series with ‘most agonising cliffhanger’ in years is finally returning

Fans have been waiting more than two years for show to return

The Independent UK

Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises

Starboard took aim at Pfizer in another blow Tuesday, saying the company has failed to deliver on what it called the "best pipeline" ever.

Investors Business Daily

Sanofi confirms €16 billion sale of painkiller Doliprane to US investors

French pharamceutical giant Sanofi has confirmed plans to sell a controlling stake in its over-the-counter unit to a US investment fund, after employment and investment guarantees relieved political controversy.

Radio France Internationale

France Bristles At Painkiller Maker's Sale To US Fund

French drugmaker Sanofi's Monday confirmation that it plans to sell a controlling stake in its over-the-counter unit to a US investment fund sparked a new political backlash, stoked by fears the deal marks a loss of sovereignty over key medications.

International Business Times

France warns US buyer of Sanofi division of penalties for shifting production abroad

Private equity firm CD&R revealed to be in exclusive talks to buy 50% stake in consumer healthcare arm Opella

The Guardian - UK

Sanofi Pursues Sale Of Painkiller After Political Controversy

Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, after employment and investment guarantees relieved political controversy.

International Business Times

Analysts revise AbbVie stock price target ahead of earnings

Here's what could happen next to AbbVie shares.

The Street

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Britons most likely in Europe to turn to unregulated alternative therapies

UK consumers are most likely patients in Europe likely to seek health advice from social media, poll suggests

Investors Business Daily

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up

The three-horse race to treat a devastating form of muscular dystrophy is now down to two. And Avidity Biosciences is feeling bullish.

StockNews.com

3 Small-Cap Biotech Stocks With Game-Changing Potential

The biotech industry offers a compelling investment opportunity due to its potential for disruptive innovations and high growth. Thus, investing in fundamentally strong small-cap stocks Esperion Therapeutics (ESPR), Innoviva, Inc. (INVA), and SIGA Technologies (SIGA) could be significantly rewarding. Read on….

International Business Times

Visionary Marc DeValera: A Story of a Miraculous Discovery Turning into a Respiratory Treatment Revolution

Passionate about returning Big Pharma's power to the people, Marc DeValera, founder of MLFD-MedTech Inc., developed 3 essential oils using a Mesh Nebulizer, an all-natural alternative to respiratory treatments.

Get all your
news in one place.

100’s of premium titles.
One news app.

Evening Standard

Best Cytoplan supplements for women in midlife

Research has found that 40 per cent of women over the age of 45 have a chronic health condition

The Guardian - UK

‘The UK is at the back of the race of turtles’: Sanofi’s boss on the need to develop new medicines

Paul Hudson, the Briton in charge of the French drug firm, is a big believer in the potential of AI to transform healthcare

Radio France Internationale

France could block sale of 'best-selling' drug if production doesn't stay local

France’s Economy Minister has warned that the government could block the sale of a subsidiary of the French pharmaceutical company Sanofi to a US private equity firm if it cannot guarantee that its production of paracetamol, under the name Doliprane, remains in France.

International Business Times

Painkiller Sale Plan To US Gives France Major Headache

The planned sale of France's best-selling medical drug to US investors has caused the government a splitting headache after an outcry against the project from politicians on all sides.

Investors Business Daily

Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade

Amgen stock dipped Monday after an analyst downgraded shares, saying the opportunity for its weight-loss drug is already baked into the stock.

The Guardian - UK

There’s an elephant in the room at Keir Starmer’s big investment summit: Brexit

We need a salvage operation to fix the problems this created. Otherwise, how else will we attract global investment, asks Labour MP Stella Creasy

Kiplinger

You Could Pay Only $2 for These Drugs Soon Under Medicare

Those enrolled in Medicare could soon pay just $2 for these prescription drugs.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

113 stories

Savanta

112 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.